ArcellxACLX
ACLX
About: Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Employees: 130
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
104% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 24
30% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 56
14.93% more ownership
Funds ownership: 92.53% [Q3] → 107.45% (+14.93%) [Q4]
11% more funds holding
Funds holding: 186 [Q3] → 207 (+21) [Q4]
10% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]
7% more capital invested
Capital invested by funds: $4.16B [Q3] → $4.46B (+$300M) [Q4]
8% more call options, than puts
Call options by funds: $35.8M | Put options by funds: $33.3M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$105
65%
upside
Avg. target
$111
75%
upside
High target
$115
80%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
UBS Ashwani Verma 44% 1-year accuracy 8 / 18 met price target | 79%upside $114 | Buy Maintained | 10 Dec 2024 |
HC Wainwright & Co. Emily Bodnar 22% 1-year accuracy 34 / 154 met price target | 80%upside $115 | Buy Reiterated | 10 Dec 2024 |
Needham Gil Blum 22% 1-year accuracy 36 / 167 met price target | 65%upside $105 | Buy Reiterated | 10 Dec 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
2 months ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
Positive
Investors Business Daily
2 months ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma.
Positive
Benzinga
2 months ago
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).
Neutral
Business Wire
2 months ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of.
Positive
Zacks Investment Research
3 months ago
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
3 months ago
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.
Negative
Zacks Investment Research
3 months ago
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago.
Neutral
Business Wire
3 months ago
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. “We believe the data from the recently published ASH abstracts continues to differentiate anito-cel's clinical profile as a potentially best-in-class.
Positive
Zacks Investment Research
3 months ago
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
3 months ago
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that it will present clinical data in a poster presentation from its Phase 1 study (abstract #4825) of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM); preliminary clinical data in an oral presentation.
Charts implemented using Lightweight Charts™